BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

Core Viewpoint - BioXcel Therapeutics, Inc. has entered into a securities purchase agreement for a registered direct offering of 4,500,785 shares of common stock at a price of $1.739 per share, along with accompanying warrants [1][3] Group 1: Offering Details - The offering includes 4,500,785 shares of common stock and warrants to purchase an equal number of shares at an exercise price of $1.614, expiring five years from issuance [1] - The transaction is expected to generate approximately $8.0 million in gross proceeds before deducting fees and expenses [3] - The closing of the offering is anticipated to occur on or about March 11, 2026, pending customary closing conditions [3] Group 2: Warrant Adjustments - The company has agreed to reduce the exercise price of existing warrants held by the investor to $1.614 per share and extend their expiration to five years from the closing of the offering [2] - The investor will pay approximately $173,000 for this adjustment in the exercise price of the warrants [2] Group 3: Company Overview - BioXcel Therapeutics, Inc. focuses on developing transformative medicines in neuroscience using artificial intelligence [6] - The company’s subsidiary, OnkosXcel Therapeutics, is dedicated to immuno-oncology drug development [6] - The company employs a drug re-innovation approach, leveraging existing approved drugs and big data to identify new therapeutic indications [6]